Board summary
Key figures
35,711
Registered population
51.6% aged 18–64
32.1%
Aged 65+
ICB 21.9% · England 17.9%
4.3%
Ethnic minority (non-White)
1.7% Asian · England 9.6%
7.5%
In IMD quintile 1
ICB 9.2% · England 21.0%
~2,435
Core20 residents (est.)
Resident basis; registered basis ~2,411 · see page 3
7,733
Hypertension register
+7.22% in 3 yrs · England +5.60%
312
SMI register
15.6% of Arun's
856
COPD register
Reviews -9.50% in 3 yrs
Forecast to 2030
9,122
Hypertension patients, 2030
+1,389 on today
74.8%
QRISK ≥20% on statins, 2030
+4.49pp over 3 yrs
7.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Annual COPD reviews fell while England rose.
Over 2023 to 2025, COPD reviews fell 9.5% (England +2.8%) to 72.7% (England 76.4%), which may reflect review capacity and remains unverified locally.
Under-80 blood pressure control lags England.
Control is 65.1% (England 67.8%), with -2.5% 3-year change (England +3.2%); Westcourt Medical Centre is 59.9%, while Willow Green Surgery reaches 71.2%.
Mental health physical checks rose well above England.
Over 2023 to 2025, blood pressure checks rose +17.8 pp to 92.7% (England 83.4%) and BMI checks reached 91.9% (England 82.1%).
Population, age and ethnicity
Of 35,711 patients, 32.1% are aged 65+ alongside 36 catchment care homes
Across 35,711 registered patients, 32.1% (11,449) are aged 65+, above Arun (29.2%), NHS Sussex Integrated Care Board (21.9%) and England (17.9%). Working-age adults (18-64) form 51.6% (Arun 54.9%; ICB 60.5%; England 62.7%) and children (0-17) form 16.4% (Arun 15.9%; ICB 17.7%; England 19.6%). Census resident estimates show 95.7% White ethnicity (Arun 95.8%; ICB 91.0%; England 81.1%) and 4.3% ethnic minority, not registered-patient counts. Despite this older profile, recorded dementia fell 1.5% over 2023 to 2025 (Arun +5.6%; ICB +2.2%; England +6.0%) to 1.2% (441 patients), which could reflect coding changes; register audits would test this.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Arun local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Arun LA) | 2,327 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.6% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 61.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Arun LA) | 1,216 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Arun LA) | 13.3 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 7.5% of PCN patients and concentrates entirely in Park Surgery
Across the PCN, 7.5% of registered patients live in Core20 areas, below Arun (9.8%), NHS Sussex Integrated Care Board (9.2%) and England (21.0%). A 0.74 percentage point reconciliation difference exists between the PCN rate and the 6.8% weighted practice share. Deprivation is entirely concentrated at Park Surgery, with a 21.5% Core20 share (an estimated 2,411 patients), while Westcourt Medical Centre and Willow Green Surgery record 0.0%. Prioritising proactive chronic disease reviews and inclusion support at Park Surgery directs Core20 resources to the only practice serving this population.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
312
SMI register
0.88% recorded prevalence
204
Learning disability register
0.57% recorded prevalence
36
Care homes, 1,249 beds
In the PCN catchment
8.9%
Provide unpaid care
Arun, Census 2021
The PCN records 204 learning disability patients (0.6%; Arun 0.8%; ICB 0.6%; England 0.6%) and 312 severe mental illness patients (0.9%; Arun 1.1%; ICB 1.1%; England 1.0%), alongside 36 catchment care homes (1,249 beds). In Arun, 16 people slept rough in autumn 2025 and 8.9% provide unpaid care (Census 2021). The gap against Arun's learning disability rate could reflect recording differences, which register searches would test.
Severe mental illness: physical health checks
Recorded SMI checks reach 92.7% for blood pressure and 91.9% for BMI, exceeding England (83.4% and 82.1%). Smoking cessation support is 93.5% (England 94.2%), but stands at 83.1% at Westcourt Medical Centre, which may warrant targeted review.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,733
Hypertension register
+7.22%
Register growth, 3 yrs
Arun +4.55% · England +5.60%
−1.64pp
BP control, under 80
≤140/90 · −0.66pp aged 80+
+1,389
More patients by 2030
Forecast 9,122 (25.01%)
Hypertension case-finding and control
Recorded hypertension prevalence is 21.8% (7,733 patients), above England (15.2%), Arun (19.8%), and NHS Sussex Integrated Care Board (16.3%). While 90.9% of hypertension patients have a recent blood pressure reading (England 90.0%), blood pressure control in patients aged under 80 fell 2.5% over 2023 to 2025 (England +3.2%) to 65.1% (England 67.8%), and control in those aged 80+ fell 0.8% (England +2.2%) to 78.4% (England 81.2%). Across practices, under-80 control ranges from 59.9% at Westcourt Medical Centre to 71.2% at Willow Green Surgery. Lower blood pressure control against England across both age cohorts may reflect differences in medication titration or review recall, which local audit could test, particularly at Westcourt Medical Centre.
Lipids and statins
For primary prevention, 64.8% of patients with QRISK ≥ 20% receive lipid-lowering therapy, above England (63.6%). However, in secondary prevention, 82.2% of diabetic patients with cardiovascular disease receive statins, trailing England (84.4%). Secondary prevention statin coverage trails England, which may warrant reviewing recall systems for diabetic patients with cardiovascular disease.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 84,351 | £2.80 | £2.42 | £1.86 | £236,183 |
| Cardiovascular (all), 2025 | 107,403 | £3.29 | £3.32 | £3.33 | £353,356 |
In 2026, the PCN spent £2.80 per item on lipid-modifying drugs across 84,351 items, compared with £1.86 in England and £2.42 in NHS Sussex Integrated Care Board, representing £79,290 more than at England's unit cost. Higher unit cost than England may reflect formulary choices, though unit cost does not establish efficiency or clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.94%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.05%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.4% (856 patients; England 1.9%) after rising +5.5% over 2023 to 2025 (England +2.6%). Annual COPD reviews fell 9.5% over 2023 to 2025 (England +2.8%) to 72.7%, below Arun (74.5%) and England (76.4%), which could reflect review capacity. Asthma prevalence is 8.7% (2,963 patients; England 6.6%), with 66.0% reviewed in the last 12 months, leaving an estimated scale gap of 1,007 patients. Asthma prescribing for ages 5-19 is 1,985 items per 1,000 (England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 6.1% (2,169 patients; England 3.8%). In childhood immunisations, 6-in-1 coverage at 12 months reaches 97.3% (England 91.0%), but 4-in-1 pre-school booster coverage at age 5 is 93.1%, below the 95.0% target by 1.9 pp. MMR second-dose coverage at age 5 is 94.8% (first dose 96.6%), with Westcourt Medical Centre recording a 5.9 pp dose difference between first dose (94.1%) and second dose (88.2%).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
Across NHS Sussex ICB in 2022, 58.5% of cancers with a known stage (4,799 of 8,209) were diagnosed at stage 1 or 2, exceeding England (55.3%) but remaining 16.5 pp below the 75.0% national ambition by 2028. Known-stage completeness was 64.3% (8,209 of 12,766; England 67.0%), meaning unrecorded staging restricts certainty. Sizing this ICB gap indicates an extra 1,357.8 (about 1,360) early-stage cases annually are needed to meet 75.0%. Within the PCN, recorded cancer prevalence is 6.1% (2,169 patients; England 3.8%), alongside cervical screening at 74.5% (England 66.8%) and breast screening at 75.4% (England 69.9%). Maintaining high screening uptake across member practices supports early detection across the PCN.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), University Hospitals Sussex NHS Foundation Trust achieved 65.2% on the 62-day cancer referral to treatment standard, 19.8 pp below the 85.0% standard, trailing Portsmouth Hospitals University NHS Trust (75.2%), Royal Surrey NHS Foundation Trust (84.5%), NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). Its 31-day combined treatment was 76.8% (standard 96.0%) and 28-day faster diagnosis was 74.0% (standard 75.0%). In diagnostic waits, 12.9% waited 6+ weeks overall, though colonoscopy reached 39.3% (England 30.8%). Acute waiting pressures may prolong diagnostic resolution for referred PCN patients.
| Pathways within standard (%) | Sussex | Portsmouth | Royal Surrey | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.01 | 66.81 | 82.62 | 79.29 | 79.32 |
| 31-day treatment (96%) | 76.79 | 94.78 | 96.43 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 65.20 | 75.20 | 84.48 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Sussex | Portsmouth | Royal Surrey | England |
|---|---|---|---|---|
| MRI | 5.62 | 50.36 | 0.00 | 21.40 |
| CT | 8.57 | 13.06 | 0.15 | 9.92 |
| Echocardiography | 0.39 | 32.75 | 1.55 | 28.48 |
| Colonoscopy | 39.35 | 82.52 | 0.00 | 30.83 |
| Gastroscopy | 20.02 | 74.88 | 0.00 | 29.02 |
| All 15 DM01 tests | 12.95 | 51.96 | 8.82 | 23.14 |
| Community services activity | West Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 78,050 | 309,615 |
| Referrals | 16,015 | 66,930 |
| Patients with a contact | 19,770 | 85,660 |
Community services (residents of West Sussex), Jun 2026 (provisional). In Jun 2026 (provisional experimental data), 19,770 West Sussex residents had 78,050 community care contacts, and adults aged 65+ accounted for 72.7% of them (56,740). NHS Surrey and Sussex Integrated Care Board recorded 309,615 contacts across 85,660 patients. High older-age community contacts point to significant opportunities for joint proactive review with local community teams.
Practice variation and patient experience
Overall QOF achievement is high, but vaccination domain achievement varies widely across practices
Overall QOF achievement exceeds England (92.5%) across all three practices, reaching 93.9% at Park Surgery, 95.3% at Westcourt Medical Centre, and 98.8% at Willow Green Surgery. Clinical achievement is also high (97.2% at Park Surgery, 100.0% at Willow Green Surgery). However, vaccination achievement spans a 28.4 pp range, from 61.8% at Westcourt Medical Centre to 90.2% at Willow Green Surgery.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Westcourt | 80 | 0.0 | 52.8% | 72.8% | 86.9% |
| Willow Green | 103 | 0.0 | 72.7% | 60.1% | 79.9% |
| Park Surgery | 104 | 21.5 | 60.8% | 46.3% | 77.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
SMI checks gained up to +19.7 pp, but 11 measures trailed England
Across 312 severe mental illness patients, checks rose over 2023 to 2025: BMI recording gained +19.7 pp to 91.9% (England +5.1 pp to 82.1%), blood pressure checks rose +17.8 pp to 92.7% (England +4.4 pp to 83.4%), and alcohol recording rose +18.3 pp to 88.3% (England +5.4 pp to 81.8%). Conversely, 11 measures trail England's change. COPD reviews fell 9.5% (England +2.8%) to 72.7% (England 76.4%), under-80 blood pressure control fell 2.5% (England +3.2%) to 65.1% (England 67.8%), and heart failure reviews reached 69.8% (England 78.5%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Dementia register
BP control, under 80
Hypertension treated to target
BP control, 80+
BMI record (SMI)
BP check (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Arun | Asset | PCN | Arun |
|---|---|---|---|---|---|
| Care homes (catchment) | 36 (1,249 beds) | n/a | Schools (catchment) | 29 | n/a |
| Children's centres | 3 | 7 | Places of worship | 19 | 68 |
| Libraries | 3 | 7 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 3 | 21 | Primary academies | 8 | 19 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Target age-five booster recall
At age 5 in Q1 2025/26, MMR coverage drops 5.9 pp from first (94.1%) to second dose (88.2%) at Westcourt Medical Centre (PCN drop 1.8 pp, 96.6% to 94.8%); PCN 4-in-1 coverage is 93.1% (below 95.0% by 1.9 pp). Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Option 2
Review lipid-modifying prescribing formulary
In 2026, the PCN spent £2.80 per item on lipid-modifying drugs across 84,351 items versus £1.86 in England and £2.42 in NHS Sussex Integrated Care Board, spending £79,290 more than at England's unit cost. Low cost, quick to run.
Evidence base: tracks pharmacological uptake of hypertension case-finding and BP control; rising volume with falling admissions is the success signal.
Policy anchor: Core20PLUS5 adults: hypertension case-finding and optimal management (CVD); Modern service frameworks for CVD, frailty and dementia, severe mental illness.
Option 3
Expand structured annual asthma reviews
Of 2,963 asthma register patients (8.7%; England 6.6%), 66.0% had a review in the last 12 months (England 65.7%), an estimated scale gap of 1,007 patients alongside 1,985 asthma items per 1,000 aged 5-19 (England 1,488). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Dementia register coding audit (p2) | Dementia register | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Targeted Core20 chronic disease outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Targeted smoking cessation review (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension titration protocol review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool immunisation recall and outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Target age-five booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Option 2 · Review lipid-modifying prescribing formulary (p12) | Cost per item for Lipid-regulating drugs 2026 · Count of Items prescribed for Lipid-regulating drugs 2026 | Core20PLUS5 approach · Neighbourhood health framework | PCN |
| Option 3 · Expand structured annual asthma reviews (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
